Zent2U is excited to announce the successful finalization of the harmonized part of the registration procedure with European authorities for Sitagliptin phosphate tablets in 25mg, 50mg and 100mg strengths. ☑️
This achievement marks a significant milestone in a project journey towards obtaining Marketing Authorization across European countries soon. 🌍
Sitagliptin Zent2U is a generic alternative to the medication Januvia® by Merck Sharp & Dohme® indicated for the treatment of type 2 diabetes mellitus in adults. 💊
We are now one step closer in our endeavor to provide our partners with high-quality and cost-effective products to enrich their portfolio of diabetes medications. 🤝
Partner up now and connect with our team today! 📧
thomas.koene@zentiva.com - Thomas Koene - Head of Zent2U
tomas.pilarcik@zentiva.com – Tomas Pilarcik – Head of B2B Europe
rahul.padhye@zentiva.com – Rahul Padhye – Head of B2B International
nina.fuentes@zentiva.com – Nina Fuentes de Tienda – Key Account Manager B2B Europe
zent2u innovation HealthcareAdvancements diabetesmellitus
